Zealand Pharmaceutical’s GLP-1 Agonist AVE0010 enters Phase III trials in Patients With Type 2 Diabete
Filed under: Uncategorized | Tagged: agonist, AVE-0010, AVE0010, GLP-1, Glucagon-like peptide 1, Sanofi-Aventis, Zealand Pharmaceuticals, ZP-10, ZP10 | Leave a Comment »
Data published in this weeks NEJM show that angiotensin II receptor antagonists delay the progression of aortic root dissection in patients with Marfan’s syndrome
Filed under: Uncategorized | Tagged: Angiotensin II AT1, antagonist, Aprovel, Avapro, Avastar, BMS, BMS-186295, BMS186295, BMS741672, Cosaar, Cozaar, Cozaarex, Dainippon Sumitomo, DuP-753, E-3340, Ex-89, EXP-3174, Irban, Irbesartan, Irbetan, Karvea, Lorzaar, losartan, MK-954, Newlotan, Nu-Lotan, Ocsaar, Paxon, Sanofi-Aventis, Shionogi, SR-47436, SR47436 | Leave a Comment »
Shionogi and Dainippon Sumitomo have announced that Irbesartan will be launched in Japan on July 1st. Shionogi licensed Irebesartan, a long-acting angiotensin II receptor blocker, from Sanofi-Aventis.
Filed under: gpcr | Tagged: Angiotensin II AT1, antagonist, Aprovel, Avapro, BMS, BMS-186295, BMS186295, Dainippon Sumitomo, Irban, Irbesartan, Irbetan, Karvea, Sanofi-Aventis, Shionogi, SR-47436, SR47436 | Leave a Comment »
Clinical data presented at ADA show Sanofi-aventis’ CB1 antagonist rimonabant significantly improved glucose levels (as measured by HbA1c) compared to controls in patients with type 2 diabetes
Filed under: gpcr | Tagged: Acomplia, antagonist, Cannabinoid, CB1, Rimonabant, Sanofi-Aventis, Slimona, SR-141716, SR-141716A, SR141716, SR141716A, Zimulti | Leave a Comment »
Phase III results released by Sanofi Aventis demonstrate that Eplivanserin improves sleep quality. The drug also shows good tolerance versus placebo
Filed under: gpcr | Tagged: 5-HT2A, 5HT2A, antagonist, eplivanserin, Sanofi-Aventis | Leave a Comment »
